clinical trial · NCT07293754
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Repertoire Immune Medicines·phase2·recruiting·n = 150
Advanced Malignant Solid TumorRPTR-1-201PD-1 / PD-L1 monoclonal antibody
brief summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
started
Dec 12, 2025
primary completion
Dec 15, 2028
completion
Apr 15, 2029
last updated
Feb 17, 2026
official title
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol